Smallcap stocks outperformed on Tuesday despite weak broader markets, with Wockhardt, Tata Tech and CAMS gaining up to 11% on strong Q4 ear...

Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...

Syngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects single-digit r...

Syngene International, the contract research and manufacturing services arm of Biocon reported a 9% year-on-year (YoY) drop in net profit t...

The earnings before interest, tax, depreciation and ammortisation dropped 1% YoY to Rs. 333 crore in Q4FY24. The EBITDA margin rose 300 bas...

Promoters held 54.8 per cent stake in the company as of 30-Jun-2023, while FIIs owned 23.19 per cent, DIIs 11.2 per cent.

Syngene International Ltd. key Products/Revenue Segments include Contract Research & Contract Manufacturing (CRAMS), Other Operating Revenu...

Syngene has raised the revenue guidance for FY23 from mid-teens to high teens due to significant depreciation of rupee against the dollar a...

Syngene is a fully integrated CRAMS company and Biocon has around 70% stake in it. Syngene also has a wholly-owned subsidiary in the US.

Syngene International Ltd., incorporated in the year 1993, is a Mid Cap company (having a market cap of Rs 24969.62 Crore) operating in Pha...

Yes Securities has a sell call on Syngene International with a target price of Rs 400. The current market price of Syngene International is...

Revenue from the operations stood at Rs 585 crore in the quarter under review. It was Rs 519 crore in December quarter 2019-20, it added.

Add Syngene International at a price target of Rs 650.

Biocon has gained nearly 9 per cent in the past six months, compared to a 2 per cent fall in the BSE benchmark Sensex.

Long-term investors should 'subscribe' to Syngene IPO which opens for subscription today, various brokerages said in a report.

Kiran Mazumdar Shaw, CMD, Biocon Ltd, tells us about the progress with the Syngene IPO and how the proceeds from the same will be used.

Bio-pharmaceuticals contributed Rs 541 crore and research services Rs 220 crore to revenue for the reporting quarter.